Encode Ideas: Plainspoken Biotech and Medtech Interviews

Mar 06 2022 353
Encode Ideas: Plainspoken Biotech and Medtech Interviews Podcast artwork

Encode Ideas authors research on publicly traded micro / small cap healthcare (biotech & medtech) companies. The Plainspoken podcast is an extension of our research, where we will interview executives from micro / small cap health care companies, portfolio managers who invest in micro / small cap healthcare, and key opinion leaders who can offer insights into therapeutics areas of interest to investors. The podcast is for entertainment purposes only and should not be considered financial advice. Our research and disclosures can be found at www.encodelp.com. For our most contemporary commentary please follow us on twitter @encodelp

RSS feed Share
Copy RSS


Subscribe on Podcast Addict


A Discussion with Jeb Besser, Managing Member at Manchester Management & CEO of Modular Medical

Mar 06 2022 59 mins  
An interview with Jeb Besser, Managing Member at Manchester Management, a $100M AUM hedge fund that makes concentrated investments in micro/small cap health care and technology companies. In February 2022, Jeb also stepped into the CEO role at Modular Medical, a development-stage insulin pump company, where Manchester is the largest shareholder. During the interview, Jeb outlines h

A Discussion with Grant Hesser, Portfolio Manager at Social Capital, and Jeremy Sobotta, CEO of Perimeter Medical Imaging AI

Feb 14 2022 54 mins  
In January 2022, Social Capital made a C$43.4 million strategic investment in Perimeter Medical Imaging AI (TSX-V: PINK, US: PYNKF) to advance Perimeter's ultra-high-resolution, real-time, imaging technology. In this podcast, we have a conversation with Grant Hesser, Portfolio Manager at Social Capital, and Jeremy Sobotta, CEO of Perimeter Medical, to better understand the attribut

A Discussion with Gil Aharon of Rosalind Advisors: Biotech Investing, Verona Pharma & Delcath Systems

Dec 12 2021 67 mins  
An interview with Gil Aharon of Rosalind Advisors, where we discuss his perspective on the macro biotech market. Having run a dedicated life science fund for 10 years, Gil puts today's difficult biotech market into historical context and offers his opinion on why investors should be optimistic for the future. During the interview, we also discuss two of Gil's favorite smaller healt

A Discussion with Brian Finn of Findell Capital: Biotech Investing, Liquidia & ProQR

Nov 30 2021 48 mins  
An interview with Brian Finn of Findell Capital, where we discuss his perspective on small-cap investing. During the interview, we discuss two of Brian's favorite health care names, Liquidia and ProQR, as well as his previous success with MiMedx. To learn more about Findell Capital please visit their website https://findell.us/ Companies discussed during the podcast; Liquidia Corpo

A Discussion with George Haywood: Biotech Investing, Synaptogenix & Petros

Nov 10 2021 57 mins  
An interview with George Haywood, a well-known investor, where we discuss his perspective on biotech investing. During the interview, we cover some of George's previous biotech successes, including AVI Biopharma / Sarepta, Martek & Amarin, and his current favorite biotech names, Synaptogenix & Petros. Companies discussed during the podcast; Synaptogenix, Inc. (Nasdaq: SNPX) Petros

Delcath Systems: Filtering Through Its Past & Future

Oct 24 2021 47 mins  
An interview with Gerard Michel, CEO of Delcath Systems, where Gerard reflects back on his time with Vericel, the decision to become CEO of Delcath, the initial NDA submission for the HEPZATO™ KIT, and the preliminary data release from the Phase 3 FOCUS study. Gerard also addresses the future for Delcath, including the impending full Phase 3 FOCUS results, future clinical indicat

Bright Minds Biosciences & Next Generation Psychedelics

Oct 10 2021 43 mins  
An interview with Gideon Shapiro, Co-Founder & VP of Discovery at Bright Minds Biosciences, where we discuss recent and upcoming events in psychedelic drug development. We cover Bright Minds pipeline of 5HT2 agonists, the importance of FDA's approval of Spravato, and Compass's impending Ph2b psilocybin data, among other topics relevant in the psychedelic space. Companies discussed